What is a GLP-1 prescription management platform in India?

A telemedicine service that connects patients with qualified endocrinologists to prescribe, monitor, and adjust GLP-1 medications (like semaglutide) for legitimate medical indications: Type 2 diabetes, cardiovascular risk reduction, and obesity as a metabolic disorder. Per Telemedicine Practice Guidelines 2020, all prescriptions must come from registered MBBS/MD doctors and include regular clinical follow-up. The platform ensures ethical use and prevents cosmetic misuse by maintaining strict medical eligibility criteria.

How much does it cost to start a GLP-1 platform in India?

₹45–65 Lakhs for MVP launch: Tech platform (₹15–20 L), medical credentialing & legal compliance (₹10 L), initial doctor network (₹8–12 L), brand & marketing (₹10–15 L), 6-month working capital (₹5 L). Scaling to 50 cities requires ₹2–3 Cr over 18 months including hiring, inventory, and insurance.

Is a GLP-1 management platform profitable in India?

Yes. With 74M diabetics in India (IDF 2024), even 5% penetration = 3.7M patients. At ₹8,000–15,000/year per patient in consultation + monitoring fees, the addressable market is ₹300–550 Cr. Unit economics: Customer acquisition cost ₹500–1,000; lifetime value ₹25,000–50,000 (3–5 year retention). Profitability expected by Year 2–3 with 50,000+ active patients.

What regulations apply to a GLP-1 management platform in India?

Key regulations: (1) Telemedicine Practice Guidelines 2020 (MoHFW) — all prescribers must be registered with Medical Council; (2) Indian Drugs & Cosmetics Act, 1940 — GLP-1 drugs are Schedule H, prescription-only; (3) Drugs & Cosmetics Rules, 1945 Section 96A — adverse event reporting to Pharmacovigilance Programme of India (PvPI) within 15 days; (4) Data Protection: comply with HIPAA-equivalent digital health standards under NDHM; (5) GST: 5% on consultation, 5% on platform services. Medical Council registration of all doctors is mandatory.

GLP-1 Prescription Management Platform India 2026 — Startup

AI SummaryIndia's GLP-1 market is projected at ₹850 Cr–₁.2 Bn by 2026, driven by 74M diabetics and 135M obese adults seeking supervised therapy. The Telemedicine Practice Guidelines 2020 now permit remote prescribing by MBBS/MD doctors, creating a regulatory window for licensed platforms. A hybrid telemedicine + in-clinic model addresses the article's core insight: GLP-1 use must shift from cosmetic self-medication to medically supervised treatment. Entrepreneurs with healthcare tech expertise, regulatory compliance knowledge, and endocrinologist networks should capture this opportunity in metros (Delhi, Mumbai, Bangalore, Hyderabad) before large hospital chains or pharma companies dominate.